Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV
Phase 3positiveBrelovitugPositive
AI Analysis
Summary
Mirum Pharmaceuticals announced that Brelovitug met its primary goal in the Phase III AZURE-1 study for hepatitis delta virus (HDV) treatment. This positive Phase 3 data readout represents a significant milestone in the clinical development program.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Met primary goal in Phase III AZURE-1 study
Importance:8/10
Sentiment:
0.85
Phase 3Clinical TrialHDVPositive Data
Related Companies
Read the original article
Published by yahoo_finance on September 29, 2026 1:20 PM